Filtered By:
Drug: Canagliflozin

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 60 results found since Jan 2013.

SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type2 diabetes mellitus
Persons with type2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a r...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research

SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
Persons with type 2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a ...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study.
Conclusions : In this high-risk cohort, initiation of SGLT2i was associated with lower ACM, HHF, and MACE and higher BKA risk. Findings underscore the potential benefit and risks to be aware of when initiating SGLT2i. It remains unclear whether the BKA risk extends across the class of medication as the study was not powered to make comparisons among individual treatments. PMID: 29133607 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2017 Category: Cardiology Authors: Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N Tags: Circulation Source Type: research

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
CONCLUSIONS : Patients with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular outcomes compared with the primary prevention patients. Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups. Additional studies will provide further insights into the effects of canagliflozin in these patient populations. CLINICAL TRIAL REGISTRATION : URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754. PMID: 29133604 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2017 Category: Cardiology Authors: Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group Tags: Circulation Source Type: research

Can we go beyond surrogates?
Two years ago, data presented at the annual American Diabetes Association (ADA) meeting in New Orleans showed a marked decrease in deaths, especially those due to cardiovascular disease, with the use of empagliflozin. Two major questions have been asked: (i) was the result a fluke; and (ii) was it a class effect, or was it specific to the agent used? The hope that both questions would be answered by a second study has been answered: the conclusions of EMPA‐REG were not an anomaly and it is a class effect, not one caused by a specific drug. Importantly, do these studies require us to alter our algorithms for the treatment...
Source: Journal of Diabetes - October 19, 2017 Category: Endocrinology Authors: Andrew Drexler Tags: Editorial Source Type: research

Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA ® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes
Source: Johnson and Johnson - October 2, 2017 Category: Pharmaceuticals Source Type: news

The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Abstract Introduction Sodium-glucose co-transporters-2inhibitors have emerged as a very promising antidiabetic drug class, with data from the two available cardiovascular trials of this class suggesting remarkable benefits in terms of cardiovascular events, total mortality and renal outcomes. Areas covered Data point toward clinically meaningful benefits from SGLT-2inhibition on a variety of cardiovascular risk factors. Empagliflozin, and to a lesser extent canagliflozin, resulted in significant reductions of an abundance of cardiovascular mortality and morbidity endpoints. SGLT-2inhibitors were also found to redu...
Source: Pharmacological Reviews - August 22, 2017 Category: Drugs & Pharmacology Authors: Imprialos KP, Stavropoulos K, Doumas M, Karagiannis A, Athyros VG Tags: Expert Rev Clin Pharmacol Source Type: research

Benefits of SGLT2 Inhibitors beyond glycemic control - A focus on metabolic, cardiovascular, and renal outcomes.
CONCLUSIONS: SGLT2 inhibitors demonstrate some positive metabolic effects. In addition, empagliflozin specifically has demonstrated reduction in cardiovascular events and delay in the progression of kidney disease in patients with T2DM and a history of cardiovascular disease. Further data is needed to assess if this is a class effect. PMID: 28814245 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - August 16, 2017 Category: Endocrinology Authors: Minze MG, Will K, Terrell BT, Black RL, Irons BK Tags: Curr Diabetes Rev Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

Update on SGLT2 Inhibitors—New Data Released at the American Diabetes Association
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are one of the newer classes of antiglycemic agents approved for the management of patients with type 2 diabetes mellitus. Due to their unique mechanism of action, SGLT2 inhibitors have shown to be beneficial beyond glucose control. The improvement in cardiovascular (CV) outcomes was first observed in the landmark EMPA-REG OUTCOMES study. Following these results, numerous CV outcome trials were designed to identify whether the beneficial CV and renal effects observed with empagliflozin are unique or a drug class effect. The benefit of SGLT2 inhibition was confirmed by the...
Source: Critical Pathways in Cardiology - July 27, 2017 Category: Cardiology Tags: Review Article Source Type: research

INVOKANA ® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program
Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions
Source: Johnson and Johnson - June 13, 2017 Category: Pharmaceuticals Source Type: news

Sodium ‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
ConclusionsSGLT2 inhibitors are an exciting addition to the list of available agents for T2DM, and may be suitable for various types of patients who need additional glycaemic control.
Source: International Journal of Clinical Practice - March 1, 2017 Category: Internal Medicine Authors: Paresh Dandona, Ajay Chaudhuri Tags: REVIEW ARTICLE Source Type: research

Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality,...
Source: Current Medical Research and Opinion - January 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
ConclusionsAvailable data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
Source: Acta Diabetologica - August 3, 2016 Category: Endocrinology Source Type: research

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes: Cardiovascular and Kidney Effects, Potential Mechanisms and Clinical Applications.
Abstract Sodium glucose co-transporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin and canagliflozin, are now widely approved anti-hyperglycemic therapies. Due to their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight. Perhaps more importantly are osmotic diuretic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and diastolic blood pressures (BP) by 4-6/1-2 mmHg, respectively, which may underlie cardiovascular and kidney benefits. SGLT2 inhibition is also associated with an acute, dose-dependent reduction in eGFR by ~5 ml/min/1.73m(2) and...
Source: Circulation - July 27, 2016 Category: Cardiology Authors: Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ Tags: Circulation Source Type: research